Syros Pharmaceuticals, Inc. (SYRS) analyst actions
Rating and price-target actions on SYRS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SYRS overview →
1 measured SYRS analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz and Grossman, LLC Initiates an Investigation into Allegations Against Syros Pharmaceuticals, Inc. (SYRS) And Encourages Stockholders to Reach Out | Press release | +1.30% | -0.65% |
Keep exploring
More SYRS: earnings → · SEC filings → · SYRS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | 309 | 0.00% | 50% |
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Adverum Biotechnologies, Inc. (ADVM) | 306 | 0.00% | 49% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.